| Name | Title | Contact Details |
|---|
UC San Diego Health Sciences has long been known as a place where discoveries are made. Today, we are known as a place where discoveries are delivered. UC San Diego Health Sciences encompasses the School of Medicine, the Skaggs School of Pharmacy and Pharmaceutical Sciences, and UC San Diego Health System, including UC San Diego Medical Center, in Hillcrest; and in La Jolla, Thornton Hospital, Moores Cancer Center, Sulpizio Cardiovascular Center; and other centers, primary and specialty practices of the UC San Diego Medical Group faculty physicians. As a top-tier academic medical center, its role is to provide leadership in improving health through research, education and patient care. UC San Diego Health Sciences has long been at the forefront of “bench-to-bedside” research, transforming patient care through discovery and innovation leading to new drugs and technologies. It is carried out every day in the hundreds of clinical trials of promising new therapies offered through UC San Diego Health System, and in the drive of our researchers and clinician-scientists who are committed to having a significant impact on patient care. At UC San Diego Health Sciences, there are many discoveries on our horizon. Our commitment is to continue our quest to cure disease, seek better treatments and train the next generation of physicians and scientists.
Med Direct Executives is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Laurels Of Norworth is a Worthington, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pacific Nano Technology div Agilent is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Volpara Health provides an advanced AI software platform that enables a high-quality, optimized and personalized cancer screening experience. From the time a patient enters a clinic to the moment they obtain key results, the Volpara Breast Health Platform collects and analyzes information to better understand a patient`s breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities. More than thirteen million women across 39 countries have had their breast density assessed by Volpara. The company`s software is installed in approximately 2000 leading facilities worldwide, including top cancer centers in the United States. Volpara Health`s technology has been the subject of more than 300 publications. The Volpara Breast Health Platform is supported by numerous patents, trademarks, and regulatory registrations, including FDA clearance and CE marking.